Futura Medical: new US Eroxon deal and positive WSD4000 women's health data

Futura Medical PLC (AIM:FUM, OTC:FAMDF, FRA:GYX) CEO Alex Duggan and head of R&D Ken James joined Proactive's Stephen Gunnion to discuss a new US commercial partnership for Eroxon and encouraging clinical data for women's sexual health candidate WSD4000. Duggan explained that Market Performance Group brings extensive consumer healthcare experience and will handle commercial execution, advertising, distribution and customer operations in the US. The arrangement shifts Futura away from a traditional licensing model, giving it greater control over brand strategy, promotional investment and product supply while leveraging MPG's market expertise. James outlined results from two WSD4000 studies — a 228-woman home user study showing high levels of reported improvement in sexual function, and a placebo-controlled study demonstrating statistically significant results — providing confidence ahead of the planned Phase 3 pivotal trial. Regulatory submissions are expected after trial completion, with a potential launch targeted for early 2028 in both the US and Europe, subject to funding. "These results really are incredibly positive," Duggan said. "It gives us a lot of confidence, both in moving towards the phase three pivotal trial, which is now significantly de-risked, but also an indication as to the likely market success." Visit the Proactive YouTube channel for more interviews with leading companies and market insights. If you enjoyed this video, please give it a like, subscribe to the channel and enable notifications so you never miss future content. #FuturaMedical #Eroxon #WSD4000 #WomensHealth #SexualHealth #ConsumerHealthcare #Biotech #HealthcareInnovation #ClinicalTrials #FDA #MedicalDevices #Investing #Stocks #SmallCaps #Proactive